Trial Outcomes & Findings for A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema (NCT NCT04797390)
NCT ID: NCT04797390
Last Updated: 2026-03-02
Results Overview
The change in average site score from baseline assessed via endoscopy using the Modified Patterson Scale. The range for each site was 0-3: Normal, Mild, Moderate, Severe. A lower score means a better outcome.
COMPLETED
NA
236 participants
Change from Baseline at 2 months, 4 months, 6 months
2026-03-02
Participant Flow
Participant milestones
| Measure |
Advanced Pneumatic Compression Device (APCD)
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Overall Study
STARTED
|
119
|
117
|
|
Overall Study
Baseline Visit
|
116
|
105
|
|
Overall Study
2-month Visit
|
108
|
94
|
|
Overall Study
4-month Visit
|
101
|
88
|
|
Overall Study
COMPLETED
|
101
|
87
|
|
Overall Study
NOT COMPLETED
|
18
|
30
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
Baseline characteristics by cohort
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=119 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=117 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
Total
n=236 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
62.7 Years
STANDARD_DEVIATION 9.8 • n=41 Participants
|
60.9 Years
STANDARD_DEVIATION 11.9 • n=35 Participants
|
61.8 Years
STANDARD_DEVIATION 10.9 • n=76 Participants
|
|
Sex: Female, Male
Female
|
26 Participants
n=41 Participants
|
32 Participants
n=35 Participants
|
58 Participants
n=76 Participants
|
|
Sex: Female, Male
Male
|
93 Participants
n=41 Participants
|
85 Participants
n=35 Participants
|
178 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
American Indian
|
0 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
1 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
4 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
Black
|
17 Participants
n=41 Participants
|
15 Participants
n=35 Participants
|
32 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
White
|
97 Participants
n=41 Participants
|
97 Participants
n=35 Participants
|
194 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
Other
|
3 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
5 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
7 Participants
n=41 Participants
|
10 Participants
n=35 Participants
|
17 Participants
n=76 Participants
|
|
Race/Ethnicity, Customized
Not Hispanic
|
112 Participants
n=41 Participants
|
107 Participants
n=35 Participants
|
219 Participants
n=76 Participants
|
|
Region of Enrollment
United States
|
119 Participants
n=41 Participants
|
117 Participants
n=35 Participants
|
236 Participants
n=76 Participants
|
|
Cancer Site
Larynx
|
35 Participants
n=41 Participants
|
19 Participants
n=35 Participants
|
54 Participants
n=76 Participants
|
|
Cancer Site
Major Salivary Glands
|
2 Participants
n=41 Participants
|
6 Participants
n=35 Participants
|
8 Participants
n=76 Participants
|
|
Cancer Site
Oral Cavity
|
45 Participants
n=41 Participants
|
57 Participants
n=35 Participants
|
102 Participants
n=76 Participants
|
|
Cancer Site
Paranasal Sinuses
|
2 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
4 Participants
n=76 Participants
|
|
Cancer Site
Pharynx
|
30 Participants
n=41 Participants
|
25 Participants
n=35 Participants
|
55 Participants
n=76 Participants
|
|
Cancer Site
HNC of Unknown Primary
|
5 Participants
n=41 Participants
|
8 Participants
n=35 Participants
|
13 Participants
n=76 Participants
|
|
BMI
|
26.8 kg/m^2
STANDARD_DEVIATION 6.0 • n=41 Participants
|
26.5 kg/m^2
STANDARD_DEVIATION 5.9 • n=35 Participants
|
26.6 kg/m^2
STANDARD_DEVIATION 5.9 • n=76 Participants
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The change in average site score from baseline assessed via endoscopy using the Modified Patterson Scale. The range for each site was 0-3: Normal, Mild, Moderate, Severe. A lower score means a better outcome.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=59 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=56 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Internal Lymphedema - Endoscopy
2-month Visit
|
-0.12 Score on a scale
Interval -0.38 to 0.0
|
-0.06 Score on a scale
Interval -0.33 to 0.11
|
|
Internal Lymphedema - Endoscopy
4-month Visit
|
-0.21 Score on a scale
Interval -0.44 to 0.0
|
-0.16 Score on a scale
Interval -0.4 to 0.0
|
|
Internal Lymphedema - Endoscopy
6-month Visit
|
-0.26 Score on a scale
Interval -0.53 to 0.0
|
-0.23 Score on a scale
Interval -0.47 to -0.01
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The changes in fat stranding using the CT Lymphedema and Fibrosis Assessment Tool (CT-LEFAT). The range for fat stranding includes 0-2: Normal, Mild Changes, Advanced Changes. A lower score means a better outcome.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=90 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=62 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Internal Lymphedema - CT Imaging
Fat Stranding Total Score Change: 2-month Visit
|
0.00 Score on a scale
Interval -0.17 to 0.2
|
0.00 Score on a scale
Interval -0.08 to 0.25
|
|
Internal Lymphedema - CT Imaging
Fat Stranding Total Score Change: 6-month Visit
|
0.00 Score on a scale
Interval -0.38 to 0.17
|
0.00 Score on a scale
Interval -0.25 to 0.25
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The changes in epiglottic thickness, and prevertebral soft tissue (PVST) using the CT Lymphedema and Fibrosis Assessment Tool (CT-LEFAT). Epiglottis and PVST are measured in mm. A lower measurement means a better outcome.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=95 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=72 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Internal Lymphedema - CT Imaging
Epiglottis Thickness Change: 2-month Visit
|
-0.10 mm
Interval -0.7 to 0.75
|
-0.20 mm
Interval -0.8 to 0.5
|
|
Internal Lymphedema - CT Imaging
Epiglottis Thickness Change: 6-month Visit
|
-0.60 mm
Interval -1.35 to 0.2
|
-0.55 mm
Interval -1.0 to 0.08
|
|
Internal Lymphedema - CT Imaging
PSVT Change: 2-month Visit
|
-0.40 mm
Interval -1.4 to 0.8
|
-0.20 mm
Interval -0.85 to 0.65
|
|
Internal Lymphedema - CT Imaging
PSVT Change: 6-month Visit
|
-0.60 mm
Interval -1.83 to 0.12
|
-1.10 mm
Interval -2.0 to -0.12
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The presence of swelling and inflammation as assessed through grading of external lymphedema via the Head and Neck Lymphedema and Fibrosis Grading criteria (HN-LEFG). A total of 9 sites are evaluated for the presence of lymphedema and graded from 1 (mild) to 3 (severe) at each site. The number of sites ranged from 0-9 with a total severity score ranging from 0-27. A lower score indicates a better outcome. A greater negative value indicates a greater reduction in swelling.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=105 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 2-month Visit
|
-1.00 Score on a scale
Interval -2.0 to 0.0
|
0.00 Score on a scale
Interval -3.0 to 1.0
|
|
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 4-month Visit
|
-1.00 Score on a scale
Interval -3.0 to 0.0
|
0.00 Score on a scale
Interval -4.0 to 1.0
|
|
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 6-month Visit
|
-2.00 Score on a scale
Interval -4.0 to 0.0
|
-1.00 Score on a scale
Interval -3.0 to 1.0
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The presence of swelling and inflammation are assessed by digital photography. A lower value means a better outcome. A greater negative value indicates a greater reduction in swelling. Three views are scored each with 30 grids. The percentage of views with visible swelling was determined. The score ranges from 0-100%.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=86 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
External Lymphedema - Digital Photography
Front View Change: 2-month Visit
|
-4.55 Percent of Grids with Swelling
Interval -12.58 to 5.39
|
-1.38 Percent of Grids with Swelling
Interval -9.09 to 6.28
|
|
External Lymphedema - Digital Photography
Front View Change: 4-month Visit
|
-4.55 Percent of Grids with Swelling
Interval -11.49 to 5.89
|
-2.17 Percent of Grids with Swelling
Interval -11.88 to 6.72
|
|
External Lymphedema - Digital Photography
Front View Change: 6-month Visit
|
-4.17 Percent of Grids with Swelling
Interval -13.76 to 6.98
|
-1.52 Percent of Grids with Swelling
Interval -11.61 to 7.12
|
|
External Lymphedema - Digital Photography
Right View Change: 2-month Visit
|
-2.42 Percent of Grids with Swelling
Interval -8.44 to 5.17
|
-1.21 Percent of Grids with Swelling
Interval -8.47 to 5.26
|
|
External Lymphedema - Digital Photography
Right View Change: 4-month Visit
|
-4.63 Percent of Grids with Swelling
Interval -13.79 to 5.36
|
-1.39 Percent of Grids with Swelling
Interval -8.01 to 9.41
|
|
External Lymphedema - Digital Photography
Right View Change: 6-month Visit
|
-2.53 Percent of Grids with Swelling
Interval -11.11 to 6.82
|
0.00 Percent of Grids with Swelling
Interval -9.07 to 9.43
|
|
External Lymphedema - Digital Photography
Left View Change: 2-month Visit
|
-2.56 Percent of Grids with Swelling
Interval -10.57 to 5.46
|
-1.67 Percent of Grids with Swelling
Interval -8.65 to 7.34
|
|
External Lymphedema - Digital Photography
Left View Change: 4-month Visit
|
0.00 Percent of Grids with Swelling
Interval -8.17 to 8.23
|
-6.04 Percent of Grids with Swelling
Interval -14.34 to 7.58
|
|
External Lymphedema - Digital Photography
Left View Change: 6-month Visit
|
-2.22 Percent of Grids with Swelling
Interval -11.28 to 7.54
|
-3.51 Percent of Grids with Swelling
Interval -12.01 to 5.06
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Lymphedema Symptom Intensity and Distress Survey-Head and Neck (LSIDS-HN) assesses the measurement characteristics of a symptom burden for participants with head and neck lymphedema. Each symptom is rated on intensity and distress using a 5-point scale (1-Slight to 5-Severe), then added together. The values represent the mean score change from baseline. Score range: 0-10 (0 = symptom not present). A lower score means a better outcome.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=101 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=88 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 2-month Visit
|
-0.26 Score on a scale
Interval -1.5 to 0.5
|
-0.46 Score on a scale
Interval -1.23 to 0.33
|
|
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 4-month Visit
|
-0.70 Score on a scale
Interval -1.67 to 0.59
|
-0.71 Score on a scale
Interval -1.32 to 0.24
|
|
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 6-month Visit
|
-0.56 Score on a scale
Interval -1.93 to 0.46
|
-0.39 Score on a scale
Interval -1.32 to 0.35
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Vanderbilt Head and Neck Symptom Survey plus General Symptom Survey (VHNSS plus GSS) assesses symptom burden and functional impairment. Values represent a median score change from baseline. Score range: 0-10. A lower score indicates a better outcome. A more negative value indicates a greater change from baseline.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 2-month Visit
|
-0.68 Score on a scale
Interval -1.38 to 0.13
|
-0.73 Score on a scale
Interval -1.48 to -0.09
|
|
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 4-month Visit
|
-0.94 Score on a scale
Interval -1.86 to -0.1
|
-1.01 Score on a scale
Interval -1.6 to -0.48
|
|
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 6-month Visit
|
-1.12 Score on a scale
Interval -2.34 to -0.2
|
-1.06 Score on a scale
Interval -1.82 to -0.43
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Quality of life is assessed using the Linear Analog Self-Assessment. The overall well-being score ranges from 0-10 (0-As bad as it can be to 10-As good as it can be). The value represents the change from baseline. A positive change indicates an improvement.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=90 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 2-month Visit
|
0.00 Score on a scale
Interval -1.0 to 2.0
|
0.00 Score on a scale
Interval 0.0 to 1.0
|
|
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 4-month Visit
|
0.00 Score on a scale
Interval 0.0 to 2.0
|
1.00 Score on a scale
Interval 0.0 to 1.0
|
|
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 6-month Visit
|
1.00 Score on a scale
Interval 0.0 to 2.0
|
1.00 Score on a scale
Interval 0.0 to 2.0
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participants not working, participant withdrawal, or death.
Work Productivity and Activity Impairment Questionnaire (WPAIQ) PRO assessment asks questions about work and activity impairment due to lymphedema and other health problems. The values represent the difference from baseline percentage. A greater negative number indicates a greater reduction in impairment. Total score range: 0-100%
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=101 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=88 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 2-month Visit
|
0.00 Percentage
Interval 0.0 to 0.0
|
0.00 Percentage
Interval 0.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 4-month Visit
|
0.00 Percentage
Interval 0.0 to 0.0
|
0.00 Percentage
Interval 0.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 6-month Visit
|
0.00 Percentage
Interval 0.0 to 0.0
|
0.00 Percentage
Interval 0.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 2-month Visit
|
0.00 Percentage
Interval -20.0 to 0.0
|
0.00 Percentage
Interval -20.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 4-month Visit
|
-5.0 Percentage
Interval -22.5 to 0.0
|
-10.0 Percentage
Interval -30.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 6-month Visit
|
0.0 Percentage
Interval -20.0 to 0.0
|
0.0 Percentage
Interval -30.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 2-month Visit
|
0.0 Percentage
Interval -9.1 to 0.0
|
0.0 Percentage
Interval -20.0 to 4.1
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 4-month Visit
|
-5.4 Percentage
Interval -23.0 to 0.0
|
-12.3 Percentage
Interval -30.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 6-month Visit
|
0.0 Percentage
Interval -20.0 to 0.0
|
-6.4 Percentage
Interval -30.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 2-month Visit
|
0.0 Percentage
Interval -30.0 to 0.0
|
0.0 Percentage
Interval -22.5 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 4-month Visit
|
0.0 Percentage
Interval -20.0 to 0.0
|
0.0 Percentage
Interval -30.0 to 0.0
|
|
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 6-month Visit
|
-10.0 Percentage
Interval -30.0 to 0.0
|
0.0 Percentage
Interval -30.0 to 0.0
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
The 8-item Perceived Medical Condition Self-Management Scale (PMCSMS) is intended to measure patients' belief that they are capable of carrying out the self-management behaviors required by their medical condition. The scale is composed of four positively worded items and four negatively worded items, each rated on a five-point Likert scale (1=Strongly Disagree to 5=Strongly Agree). Negatively worded items are reversed scored, yielding a total score ranging from 8 to 40, with a higher score indicating stronger belief of perceived self-management competence.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 2-month Visit
|
0.00 Score on a scale
Interval -0.38 to 0.25
|
0.00 Score on a scale
Interval -0.5 to 0.34
|
|
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 4-month Visit
|
0.00 Score on a scale
Interval -0.38 to 0.25
|
0.00 Score on a scale
Interval -0.25 to 0.38
|
|
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 6-month Visit
|
0.00 Score on a scale
Interval -0.38 to 0.25
|
0.00 Score on a scale
Interval -0.53 to 0.25
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Body Image Quality Life Inventory (BIQLI) assesses participants' body image using 7 point scale ranging from -3 (very negative) to +3 (very positive). Score range: -57 to +57. The values represent the change from baseline. A higher score indicates a better outcome.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Body Image - Body Image Quality of Life Inventory
Total Score Change: 6-month Visit
|
4.0 Score on a scale
Interval -5.0 to 18.5
|
2.0 Score on a scale
Interval -3.0 to 16.2
|
|
Body Image - Body Image Quality of Life Inventory
Total Score Change: 2-month Visit
|
4.0 Score on a scale
Inter-Quartile Range SD • Interval -6.2 to 15.0
|
2.0 Score on a scale
Interval -6.2 to 14.8
|
|
Body Image - Body Image Quality of Life Inventory
Total Score Change: 4-month Visit
|
3.0 Score on a scale
Interval -10.5 to 17.5
|
2.0 Score on a scale
Interval -6.0 to 14.0
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Diet modifications will be assessed using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24). The ASA24 is a tool from National Cancer Institute (NCI) that enables multiple automatically coded self-administered 24-hour recalls and food records. Changes in total caloric intake will be evaluated.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=87 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=77 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 2-mo Visit
|
308.0 kcal
Interval -370.0 to 755.0
|
182.5 kcal
Interval -338.0 to 730.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 4-mo Visit
|
212.0 kcal
Interval -265.0 to 862.5
|
257.0 kcal
Interval -229.5 to 905.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 6-mo Visit
|
125.5 kcal
Interval -342.0 to 698.8
|
18.0 kcal
Interval -541.5 to 626.0
|
PRIMARY outcome
Timeframe: Change from Baseline at 2 months, 4 months, 6 monthsPopulation: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.
Diet modifications will be assessed using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24). The ASA24 is a tool from National Cancer Institute (NCI) that enables multiple automatically coded self-administered 24-hour recalls and food records. Changes in total fat, carbohydrate, fiber, sugars, and protein will be evaluated.
Outcome measures
| Measure |
Advanced Pneumatic Compression Device (APCD)
n=87 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
|
Usual Care
n=77 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
|
|---|---|---|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 6-mo Visit
|
9.5 grams
Interval -17.0 to 33.8
|
-7.5 grams
Interval -52.2 to 31.8
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 2-mo Visit
|
0.0 grams
Interval -33.0 to 31.0
|
6.5 grams
Interval -13.0 to 29.8
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 4-mo Visit
|
5.0 grams
Interval -12.0 to 42.5
|
7.0 grams
Interval -30.5 to 45.5
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 6-mo Visit
|
-1.5 grams
Interval -26.2 to 14.8
|
0.0 grams
Interval -24.2 to 24.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 2-mo Visit
|
9.0 grams
Interval -14.0 to 36.0
|
13.0 grams
Interval -10.5 to 43.8
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 4-mo Visit
|
12.0 grams
Interval -15.5 to 49.5
|
12.0 grams
Interval -3.5 to 51.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 6-mo Visit
|
2.5 grams
Interval -19.0 to 32.2
|
11.5 grams
Interval -19.5 to 34.8
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 2-mo Visit
|
36.0 grams
Interval -34.0 to 116.0
|
12.0 grams
Interval -45.2 to 63.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 4-mo Visit
|
23.0 grams
Interval -47.5 to 94.0
|
3.0 grams
Interval -46.5 to 91.5
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 6-mo Visit
|
29.0 grams
Interval -32.2 to 81.5
|
-8.5 grams
Interval -82.8 to 81.8
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 2-mo Visit
|
1.0 grams
Interval -6.0 to 5.0
|
1.0 grams
Interval -4.0 to 6.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 4-mo Visit
|
0.0 grams
Interval -4.0 to 6.0
|
2.0 grams
Interval -2.0 to 6.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 6-mo Visit
|
1.0 grams
Interval -5.0 to 7.0
|
0.0 grams
Interval -4.0 to 4.2
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 2-mo Visit
|
13 grams
Interval -14.0 to 63.0
|
3.0 grams
Interval -27.2 to 35.0
|
|
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 4-mo Visit
|
10.0 grams
Interval -24.5 to 36.0
|
3.0 grams
Interval -33.0 to 40.5
|
Adverse Events
Advanced Pneumatic Compression Device (APCD)
Usual Care
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60